Author:
Buda Piotr,Friedman-Gruszczyńska Joanna,Książyk Janusz
Abstract
Kawasaki disease (KD), an acute, generalized vasculitis, is associated with an increased risk of coronary heart disease and is the most common cause of acquired heart disease in childhood. The incidence of KD is increasing worldwide. There are numerous international treatment guidelines. Our study aims to perform the first one so far comparison of them. While the gold standard therapy remains still the same (intravenous immunoglobulins and aspirin), there is currently a lack of evidence for choosing optimal treatment for high-risk patients and refractory KD. In this review, we also discuss the treatment of complications of KD and Kawasaki-like phenotypes, present an anti-inflammatory treatment in the light of new scientific data, and present novel potential therapeutic targets for KD.
Reference147 articles.
1. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children;Kawasaki;Japanese J Allergol.,1967
2. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan;Kawasaki;Pediatrics.,1974
3. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins;Gardner-Medwin;Lancet.,2002
4. Increasing incidence of Kawasaki disease in Japan: nationwide survey;Nakamura;Pediatr Int.,2008
5. Kawasaki syndrome in the United States 1976 to 1980;Bell;Am J Dis Child,1983
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献